Last update 25 Mar 2025

Olodaterol Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
BI-1744-CL (hydrochloride), Olodaterol, Olodaterol hydrochloride (JAN/USAN)
+ [7]
Action
agonists
Mechanism
β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H27ClN2O5
InChIKeyKCEHVJZZIGJAAW-FERBBOLQSA-N
CAS Registry869477-96-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pulmonary Disease, Chronic Obstructive
Singapore
24 Feb 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pulmonary EmphysemaPhase 3
Japan
12 Feb 2016
XerophthalmiaPhase 2
Japan
07 Feb 2023
Persistent asthmaPhase 2
United States
01 Mar 2011
Persistent asthmaPhase 2
Austria
01 Mar 2011
Persistent asthmaPhase 2
Germany
01 Mar 2011
Persistent asthmaPhase 2
Hungary
01 Mar 2011
Persistent asthmaPhase 2
Slovakia
01 Mar 2011
Persistent asthmaPhase 2
Slovenia
01 Mar 2011
AsthmaPhase 2
Netherlands
01 Mar 2007
Intermittent asthmaPhase 2
Canada
01 Jan 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Tiotropium/Olodaterol (Tio/olo)
cvbpagannl(oqnrdocfkk) = hqtdzuefgx uyvdvgjnmt (zuwokliznp, 86)
-
03 May 2021
Tiotropium (Tio)
cvbpagannl(oqnrdocfkk) = kxkzzqkvru uyvdvgjnmt (zuwokliznp, 60)
Not Applicable
-
Tiotropium/Olodaterol Respimat
kpzpxwtafw(umtoexrdey) = hbykpyhgbu fhqyjkfhuo (qnpgtyvcis, 0.270 - 0.396)
-
03 May 2021
Placebo
kpzpxwtafw(umtoexrdey) = jlqtatkeax fhqyjkfhuo (qnpgtyvcis, -0.049 to 0.073)
Phase 3
9,942
jchebqbeui(qjwjywbwoe) = vomdnbcgli uglckoaehk (rmglsbrztt )
Positive
10 Aug 2020
jchebqbeui(qjwjywbwoe) = qijoibzptd uglckoaehk (rmglsbrztt )
Phase 3
1,078
uzgsqzenpt(jhwyqzgzia) = jeiexmqzub yhkyweqtgs (vsnrpkbudf, 0.033 - 0.079)
-
15 Jul 2020
Phase 4
302
(Tiotropium+Olodaterol (5μg/5μg) - Main Study)
hsagqxrxqf(choeyyisft) = wmhpaniwhm zhsalonkvn (jpqnayjwbh, 0.019)
-
16 Apr 2020
(Fluticasone Propionate+Salmeterol (500μg/100μg) - Main Study)
hsagqxrxqf(choeyyisft) = vwuoonaktx zhsalonkvn (jpqnayjwbh, 0.019)
Not Applicable
506
tiotropium/olodaterol 5/5 µg combination therapy
fwglxugetv(vzzdrjmldi) = imvkmstqft fjeyaqauaa (bsaujploam )
-
01 Jan 2020
fwglxugetv(vzzdrjmldi) = ruueotcpdm fjeyaqauaa (bsaujploam )
Not Applicable
78
ereasxsilv(maouroccdr) = rjrxnuiwfk usrnvwionv (rwxycbqhiw )
Positive
28 Sep 2019
ereasxsilv(maouroccdr) = mxxpofsymf usrnvwionv (rwxycbqhiw )
Phase 4
76
Salmeterol FDC+Fluticasone Propionate
(Fluticasone Propionate + Salmeterol FDC (F+S 1000/100))
xksmmxxacp(anjlwxyvxh) = pahswznohk kndivdbecd (cuebrbwblo, 1.137)
-
16 Aug 2019
(Tiotropium + Olodaterol FDC (T+O 5/5))
xksmmxxacp(anjlwxyvxh) = lopzhfkvdd kndivdbecd (cuebrbwblo, 1.136)
Phase 3
184
(Tiotropium 5 μg)
rsaorqihwk(ssooerjpvv) = sicegcbfcr qoyvidnmtq (dlyupojjwk, 0.019)
-
06 Jun 2019
(Tiotropium + Olodaterol 5/5 μg)
rsaorqihwk(ssooerjpvv) = pvwwxfgtvx qoyvidnmtq (dlyupojjwk, 0.019)
Phase 1
12
vjrmqugpey(fwhnmdvcbo) = pefsvybtzn abptggnavh (jvxespjjsa, bupbkaykea - zodrrndfnj)
-
29 Mar 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free